This diverse biologic activity of TGR5 has led to investigations of targeted therapeutic approaches in human medicine for the treatment of obesity [109], type 2 diabetes [110], and inflammatory diseases [111]. This evidence concerns the gene GPBAR1 and obesity due to melanocortin 4 receptor deficiency.